
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort Inc. reported a total revenue of $44 million, reflecting a 15% year-over-year organic growth rate, which shows a slight improvement from the previous quarter's 14% growth. The company's strong performance is supported by an increasing number of gene therapy programs in various stages of development, particularly in oncology and rare diseases, indicating a robust pipeline in the biopharma sector. With the expected rise in both commercial revenue and clinical trial activity driven by the growing acceptance of cell and gene therapies, the outlook for CryoPort remains positive.
Bears say
CryoPort Inc. is experiencing a slowdown in demand for its Life Sciences Services, with revenue growth decreasing from 21% to 16% quarter-over-quarter, despite exceeding consensus expectations. Additionally, the company's adjusted EBITDA margin remains negative at (1.5%), although it improved year-over-year, it fell short of the consensus estimate of (1.0%). The outlook is further complicated by expectations of reduced revenue growth stemming from fewer-than-anticipated cell and gene therapy approvals, alongside a decline in demand for critical equipment, leading to lowered earnings per share projections for 2026.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares